Skip to main content

Blood Sugar

Twitter Summary: Novo Nordisk’s Xultophy gets positive recommendation in Europe, full approval to hopefully come soon! On July 25, Novo Nordisk announced that the...
Twitter summary: FDA approves Xigduo XR – first once-daily SGLT-2 inhibitor/metformin fixed dose combo in the US AstraZeneca recently announced that the FDA approved...
How many different factors can affect blood glucose? See the 22 things that can change your blood sugar in the short-term...
Twitter summary: Roche launches first-ever BGM with built-in bolus calculator – important advance for MDI patients At the recent AADE conference , this August, Roche...
On June 12, iHealth Lab announced the launch of the Align blood glucose meter, a very small device that plugs directly into the headphone jack of an Apple iOS- or...
14-day sensor to replace glucose meters, but provide CGM-like info. Now available in Europe. When is it coming to the US? Read more for our full experience testing this...
Larger capacity reservoir will bring pump therapy to those with high insulin needs.
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
Major A1c improvements, weight loss, and no injections!
First-ever SGLT-2/DPP-4 inhibitor drug, will this combination cut costs for patients?
Twitter summary: Major updates from @MDT_Diabetes on the 640G predictive #insulin suspend for #diabetes from #ATTD2015
Incredible enthusiasm continues for the 14-day sensor that replaces fingersticks.
Submitted to the FDA and could be approved this year.
How this two-week trial looks to bring the Libre technology to health care.
What this dramatic movement in obesity therapy means for patients in Europe.
Twitter summary: UCSF launches SugarScience, an initiative on sugar’s dangerous health impacts. Visit SugarScience.org for more information A group of health scientists...
What I learned from doubling my carb intake: more work, more danger, but the same average blood sugar. Huh?
The two organizations expand their research partnership to support glucose responsive insulin.
Plus, exciting details on Google’s glucose-sensing contact lens!
My somewhat-impatient response to the recent New York Times article, “Some Older Patients Are Treated Not Wisely, but Too Much.”

Pages